Report out 6 May Q1e: sales SEK 39m, +2% y-o-y, EBIT SEK 0.
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phas...
Redeye was hoping for a bit more in Q1, despite adverse market conditions related to macroeconomic u...
Redeye comments on BONESUPPORT’s CEO change announced yesterday.
Orders +7%, sales -1%, adj. EBITA +28% vs. our estimates Key takeaway is the continued order strengt...
Relais announced it will acquire Team Verksted Holding AS from Vy Buss AS, making it the largest ope...
Sales +29%, adj. EBITA +20%, +29% org. growth '25e-'27e EBITA estimates to increase by 1-3% Share to...
Adj. EBITA -12% vs cons, but organic growth better Est's down 3-4%, but better growth outlook mainta...
Redeye considers Arise’s Q1 2025 report to be a mixed bag, although largely in line with our estimat...
Sales 1% below cons, adj. EBITA in line with cons Consensus EBITA estimate revisions flat to slightl...
Redeye comments on Formpipe’s Q1 report showing an ACV and EBITDA – CAPEX roughly matching our expec...
Sales SEK 9.5m, EBIT SEK -14m (vs. ABGSCe 9.5m and -20m) No system deliveries in the quarter, as exp...
Redeye provides its first take on Cellavision’s Q1 report 2025, published this morning.
Redeye believes Sdiptech's Q1 report was solid despite a drop in organic sales and adjusted EBITA wh...
Redeye comments on M.O.B.A. Network’s Q1 2025 report, which came in below our expectations.
